Glycopyrrolate Injection
FDA Label NDC 0641-6213

39 label sections · Submitted to the FDA by Hikma Pharmaceuticals Usa Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Hikma Pharmaceuticals Usa Inc. for the product Glycopyrrolate (NDC 0641-6213). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1.1 preanesthetic, 1.2 intraoperative, 1.3 reversal of neuromuscular blockade, 1.4 peptic ulcer, 2.1 important dosage and administration instructions, 2.2 recommended dosage of preanesthetic medication in adults and pediatric patients, 2.3 recommended dosage as intraoperative medication to counteract drug-induced or vagal reflexes and their associated arrhythmias (e.g., bradycardia) in adults and pediatric patients, 2.4 recommended dosage for reversal of neuromuscular blockade in adults and pediatric patients, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.